Cargando…
EPEN-38. EZH2 INHIBITORY PROTEIN (EZHIP/Cxorf67) EXPRESSION IS HIGHLY CONCORDANT WITH H3K27me3 LOSS AND IS A PROMISING SURROGATE MARKER FOR POSTERIOR FOSSA TYPE A EPENDYMOMAS
BACKGROUND: Gene expression and DNA methylation have identified 2 distinct clinicopathological subgroups among the WHO Grade II/III posterior fossa (PF) ependymomas (EPN), of which the PF-A molecular subgroup associates with poor outcome. OBJECTIVE: To analyse the utility of immunohistochemistry for...
Autores principales: | Nambirajan, Aruna, Rajeshwari, Madhu, Boorgula, Meher, Doddamani, Ramesh, Singh, Manmohan, Garg, Ajay, Suri, Vaishali, Sarkar, Chitra, Sharma, Mehar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715886/ http://dx.doi.org/10.1093/neuonc/noaa222.173 |
Ejemplares similares
-
EPEN-03. USP7 is an interaction partner of EZHIP and potential druggable target in PFA ependymomas
por: Jenseit, Anne, et al.
Publicado: (2022) -
EPEN-20. EZHIP/CATACOMB COOPERATES WITH PDGF-A AND p53 LOSS TO GENERATE A GENETICALLY ENGINEERED MOUSE MODEL FOR POSTERIOR FOSSA A EPENDYMOMA
por: Kagan, Emily, et al.
Publicado: (2020) -
EPEN-20. PDL1 expression and tumor-infiltrating immune cell subpopulations: The role of immune-checkpoint molecules in the prognosis of patients with supratentorial ependymoma and its correlation to survival
por: Malik, Rafat, et al.
Publicado: (2022) -
EPEN-08. THE TREM1 POSITIVE HYPOXIC MYELOID SUBPOPULATION IN POSTERIOR FOSSA EPENDYMOMA
por: Willard, Nicholas, et al.
Publicado: (2021) -
EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA
por: Donson, Andrew, et al.
Publicado: (2021)